GlassScriptPhysician profile
Bethlehem Addis
NPI 1417445107
$3,219.26
in general payments reported to CMS, 2019-2025
27 companies · $811 in 2025
The $811 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $718 · 2023: $848 · 2024: $513 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.44 |
| Education | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $718.20 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $266.09 | 2021-2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $198.82 | 2022-2024 | |
| Abbvie INC. | $146.28 | 2023-2024 | |
| Dexcom, INC. | $135.37 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Neurocrine Biosciences, INC. | $127.49 | 2023 | Ingrezza |
| Urovant Sciences INC | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $119.61 | 2023 | |
| Amarin Pharma, INC. | $117.35 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.05 | 2024 | |
| Bioprotect Medical, INC. | $110.37 | 2025 | Bioprotect Balloon Implant System |
| Becton, Dickinson and Company | $107.14 | 2022 | |
| Merck Sharp & Dohme LLC | $102.20 | 2023 | Lynparza |
| Kci USA, INC. | $98.08 | 2023 | V.A.C. Dermatac, Kerramax Care, 3m Cavilon |
| Phathom Pharmaceuticals, INC. | $97.05 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $86.27 | 2022 | |
| Emd Serono, INC. | $80.31 | 2024 | |
| Sage Therapeutics, LLC | $79.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $76.32 | 2024 | Uzedy |
| Tempus Ai, INC | $59.06 | 2024-2025 | Xt Cdx |
| Evofem Biosciences, INC. | $55.78 | 2021 | |
| Lilly USA, LLC | $52.62 | 2022 | |
| Olympus America INC. | $47.49 | 2023-2024 | Itind System |
| Novartis Pharmaceuticals Corporation | $43.55 | 2025 | |
| Procept Biorobotics Corporation | $19.36 | 2023 | Aquabeam Robotic System |
| Medtronic, INC. | $18.29 | 2023 | Interstim |
| Intuitive Surgical, INC. | $17.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethlehem Addis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.